



SARS-CoV-2 Rapid Antigen Test *Enables fast decision-making to help limit further spread*

The SARS-CoV-2 Rapid Antigen Test and SARS-CoV-2 Rapid Antigen Test Nasal allow for fast decentralised testing at the point of care, with results available within 15 to 30 minutes. No instrument or specialised equipment is required. They are useful in expanding testing availability into diverse settings outside the laboratory, including rural/remote and low infrastructure areas.¹

These rapid antigen tests are useful for medical or healthcare practitioners to test individuals suspected of COVID-19, or with known or suspected exposure to SARS-CoV-2. They provide a rapid and economical means to help decide if an individual may need to be quarantined/isolated, or whether further testing is needed.²

Main benefits

- » No analyser required
- » Fast results with a 15 minute turn around time
- » Prefiled reagents to ensure simple ease of use, minimal handling steps, and reduced risk of manual errors
- » Virus inactivation is achieved in the buffer after 2 minutes
- » Sample options: test sample directly from patient; and for NP test, a sample already contained in viral or universal transport media
- » Storage: test kits can be stored at room temperature

Getting fast answers is just a few steps away

Performing the Roche SARS-CoV-2 Rapid Antigen Test



sample with the supplied

swab.



extraction buffer tube

and mix.



Remove the swab while squeezing the sides of the tube and replace cap.

3



Apply 3 drops of extracted sample to the test device.






Collect the nasal sample with the supplied swab from each nostril.



Insert the swab into an extraction buffer tube and mix. Remove the swab while squeezing the

sides of the tube and replace cap.

4 drops





Read the test result at 15 - 30 min.

Nasal sampling can help reduce overall patient discomfort, particularly in sensitive individuals such as children, elderly people and/or people with disabilities.



Delivering reliable results at the point of care^{3,4,5}

SARS-CoV-2 Rapid Antigen Test

Sensitivity	95.5% (Ct value ≤ 30; 95% Cl: 91.8% - 97.8%)
Specificity	99.2% (95% Cl: 98.2% - 99.7%)

SARS-CoV-2 Rapid Antigen Test Nasal

Sensitivity	82.7 % (95 % Cl: 75.6 % - 88.4 %)
Specificity	99.1 % (95 % Cl: 97.9 % - 99.7 %)


Reference:

- Subject to the current TGA conditions on inclusion specifically for rapid antigen point-of-care tests. (https://www.tga.gov.au/applying-tga-assessment-covid-19test-inclusion-artg)
- 2. Refer to the current instructions for use for full information.
- 3. Compared to an FDA EUA authorised laboratory based real time reverse transcription PCR test.
- 4. SARS-CoV-2 Rapid Antigen Test Product Information AU V3.0.
- 5. SARS-CoV-2 Rapid Antigen Test Nasal Product Information AU V2.0.

Assay Characteristics

Test type	Qualitative - rapid chromatographic immunoassay
Sample type	 Direct collection from patient Nasopharyngeal: Sample contained in VTM/UTM
Target antigen	Nucleocapsid (N)
Time to result	15 minutes
Time to read result	Between 15 & 30 minutes
Storage temperature	Store the kit at 2-30°C / 36-86°F out of direct sunlight. Do not freeze.
Stability	NP: Up to 1 hr (15-25°C) or 4 hr (2-8°C) / Nasal: Up to 4 hr (15-25° C or 2-8°C)
Registration	Included on ARTG 352250

Understanding the results when you need to know



Test Description

Antigen Test SARS-CoV-2 Rapid


SARS-CoV-2 Rapid

Antigen Control Kit

SARS-CoV-2 Rapid

Antigen Test Nasal* SARS-CoV-2 Antigen

Control Swab



Quantity Per Kit

10 sets of positive


10 each of positive

and negative controls

and negative


25

25



In case of a positive result, a coloured test line T appears in the lower section of the result window.

Positive



In case of a negative result, only the control line C appears.

If no control line C is visible, the test is always invalid.

Invalid

SARS-CoV-2 Rapid Ag

SARS-CoV-2 Rapid Ag

	SARS-CoV-2 Rapid Antigen Test 25 Th
Catalogue Number	$ \left\{ \begin{array}{c} \left\{ \begin{array}{c} \mathbf{c} \in \mathbf{C} \mbox{ (a)} \\ \mathbf{c} \in \mathbf{C} \mbox{ (b)} \mbox{ (b)} \\ \mathbf{c} \in \mathbf{C} \mbox{ (b)} (b$
09327592023, 09327592043	Management (S
	SARS-CoV-2 Rapid Antigen Test 25 W
09338322190	SARS COV 2 Rayle Antigen Ten
09365397043	
09396276043	
ANS-Cal-2 Route Antenna ANS-Cal-2 Route Antenna ANS-Ca	
Available from	国际系统委任
tec	medical X
	ed.com.au/covid eammed.com.au 2 44 50

*1 x positive and negative QC included in the SARS-CoV-2 Rapid Antigen Test Nasal kit

All trademarks mentioned herein are protected by law. © 2021 Roche Diagnostics.

Roche Diagnostics Australia Pty Limited 2 Julius Avenue North Ryde NSW 2113 Australia ABN 29 003 001 205 Phone: 02 9860 2222 E-mail: australia.dia_cardiology@roche.com.au

MC-AU-00937